More superbugs, fewer drugs. How can pharma companies ensure the handful of promising antimicrobials make it to the frontlines of drug resistance?

With the antimicrobial research and development pipeline getting smaller, the Access to Medicine Foundation has released a new paper examining what can be done with the limited amount. The report describes how thorough access and stewardship planning may guarantee that newly-developed medications reach every patient who needs them, focusing on five late-stage programs that target some of the most severe drug-resistant infections.